RT Journal Article
T1 Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC)
A1 Campa, Daniele
A1 Hüsing, Anika
A1 Stein, Angelika
A1 Dostal, Lucie
A1 Boeing, Heiner
A1 Pischon, Tobias
A1 Tjønneland, Anne
A1 Roswall, Nina
A1 Overvad, Kim
A1 Nautrup Østergaard, Jane
A1 Rodríguez, Laudina
A1 Sala, Núria
A1 Sanchez-Perez, Maria-Jose
A1 Larrañaga, Nerea
A1 Huerta, José María
A1 Barricarte, Aurelio
A1 Khaw, Kay-Tee
A1 Wareham, Nicholas
A1 Travis, Ruth C.
A1 Allen, Naomi E.
A1 Lagiou, Pagona
A1 Trichopoulou, Antonia
A1 Trichopoulos, Dimitrios
A1 Palli, Domenico
A1 Sieri, Sabina
A1 Tumino, Rosario
A1 Sacerdote, Carlotta
A1 van Kranen, Henk
A1 Bueno-de-Mezquita, H Bas
A1 Hallmans, Göran
A1 Johansson, Mattias
A1 Romieu, Isabelle
A1 Jenab, Mazda
A1 Cox, David G
A1 Siddiq, Afshan
A1 Riboli, Elio
A1 Canzian, Federico
A1 Kaaks, Rudolf
K1 Variación genética
K1 Neoplasias de la Próstata
K1 Serina-Treonina Quinasas TOR
K1 EPIC
K1 Estudio Multicéntrico
AB The mTOR (mammalian target of rapamycin) signal transduction pathway integrates various signals, regulating ribosome biogenesis and protein synthesis as a function of available energy and amino acids, and assuring an appropriate coupling of cellular proliferation with increases in cell size. In addition, recent evidence has pointed to an interplay between the mTOR and p53 pathways. We investigated the genetic variability of 67 key genes in the mTOR pathway and in genes of the p53 pathway which interact with mTOR. We tested the association of 1,084 tagging SNPs with prostate cancer risk in a study of 815 prostate cancer cases and 1,266 controls nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). We chose the SNPs (n = 11) with the strongest association with risk (p<0.01) and sought to replicate their association in an additional series of 838 prostate cancer cases and 943 controls from EPIC. In the joint analysis of first and second phase two SNPs of the PRKCI gene showed an association with risk of prostate cancer (ORallele = 0.85, 95% CI 0.78–0.94, p = 1.3×10−3 for rs546950 and ORallele = 0.84, 95% CI 0.76–0.93, p = 5.6×10−4 for rs4955720). We confirmed this in a meta-analysis using as replication set the data from the second phase of our study jointly with the first phase of the Cancer Genetic Markers of Susceptibility (CGEMS) project. In conclusion, we found an association with prostate cancer risk for two SNPs belonging to PRKCI, a gene which is frequently overexpressed in various neoplasms, including prostate cancer.
PB Public Library of Science
YR 2011
FD 2011-02-23
LK http://hdl.handle.net/10668/253
UL http://hdl.handle.net/10668/253
LA en
NO Campa D, Hüsing A, Stein A, Dostal L, Boeing H, Pischon T, et al. Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC). PLoS One. 2011 Feb 23; 6 (2) :e16914
DS RISalud
RD Apr 9, 2025